Globe Life Says Its Group Health Startup Could Still Lose Money In 2027
Co-CEO Frank Svoboda said Every, a startup group health unit, may post losses next year, though smaller than in 2026.
Globe Life's startup group health business, Every, posted an underwriting loss of nearly $16 million in the third quarter, and co-CEO Frank Svoboda said on the company's earnings call that losses could continue in 2027. Globe Life, an insurance holding company selling life and supplemental health coverage, saw high-severity claims at Every drag down its United American division.
A loss that may not end in 2026
Svoboda said on the call there is "at least the possibility that there's some loss" at Every in 2027. He said he does not expect it to be as significant as what the company has incurred in 2026.
Co-CEO Matt Darden said the quarter's loss came from an unusually high number of high-severity claims. He described them as cancer and heart attacks, with some claimants above $100,000. Reinsurance kicks in only at some point above that, Darden said, so a handful of big claims weigh heavily on a small book.
Every sells market-group health insurance through brokers and sits inside United American. That division's health underwriting margin was negative $6 million, against a positive $16 million a year earlier. Darden said excluding Every and nearly $7 million of excess Medicare supplement claims tied to a processing delay at the federal Medicare agency, the margin would have been a positive $16 million, about 7% of premium.
Small book, 70% declined
CFO Tom Kalmbach said Every's third-quarter premiums were about $11 million. The unit has about 30 groups now and Globe Life expects around 50 next year, with annualized premium of around $100 million.
Responding to an analyst at Evercore ISI, Darden said the company declined to quote more than 70% of the cases it reviewed. He said Globe Life will constrain growth, and will moderate it or non-renew groups if needed. Darden added that premium is earned evenly over the year while claims arrive unevenly, and that groups can be repriced at each renewal.
Darden said the book should reach credible size toward the end of 2027 or the end of 2028. Kalmbach called 2027 the starting point of gaining solid credibility.
Guidance leaves room for volatility
Kalmbach said 2027 health underwriting margin guidance of 20% to 24% of premium is a wider range than before, reflecting the chance of more volatility. Globe Life guided 2027 net operating earnings to $16.10 to $17.10 per diluted share, up 7% at the midpoint. It lowered 2026 guidance to $15.35 to $15.65.
United American's net health sales rose 95% from a year earlier to $48 million, which Darden tied mainly to Medicare supplement demand. Kalmbach said the company expects the impact of Every's high-severity claims to improve in the fourth quarter, and that he would give updated guidance after those results.
Management plans to update its 2027 health margin outlook on the next call, after fourth-quarter results show whether Every's claims ease.
Sources
- Globe Life (GL) Lags Q3 Earnings and Revenue Estimates — Yahoo Finance
- Globe Life Sees FY2027 Adj EPS 17.10 ... — benzinga.com
- GL Gains From Premium Growth, AI Adoption and Higher Investment Income — Yahoo Finance
- Globe Life Lowers FY2026 Adj EPS Guidance fro... — benzinga.com
- Globe Life: Q3 Earnings Snapshot — Associated Press